Drug
Deutetrabenazine clinical trials
Also written Austedo and SD-809.
- studies test it
- 13
- open now
- 1
- in phase 3
- 7
- first study started
- 2013
Keep track of what changes. Save the deutetrabenazine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
13 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 4 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Auspex Pharmaceuticals, Inc. (5) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Vanderbilt University Medical Center (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · University of Pennsylvania (1) · University Hospitals Cleveland Medical Center (1) · Fundacion Huntington Puerto Rico (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses deutetrabenazine is read from its arms, and is right about nine times in ten.
Testing it · 13
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental DisabilitiesRecruitingPhase 4University Hospitals Cleveland Medical CenterNCT06997198Written as Deutetrabenazine Oral Capsule
- Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in ChinaCompletedPhase 4Teva Branded Pharmaceutical Products R&D LLCNCT07601516Written as Deutetrabenazine
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington DiseaseActive, not recruitingPhase 2/3Vanderbilt University Medical CenterNCT04713982Written as Deutetrabenazine
- Addressing Involuntary Movements in Tardive DyskinesiaCompletedPhase 3Auspex Pharmaceuticals, Inc.NCT02291861Written as SD-809
- Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HDTerminatedPhase 1Fundacion Huntington Puerto RicoNCT04301726Written as Deutetrabenazine Oral Tablet [Austedo]
- An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsToniaCompletedPhase 1/2University of PennsylvaniaNCT04173260Written as Deutetrabenazine 6 MG
- Reducing Involuntary Movements in Participants With Tardive DyskinesiaCompletedPhase 3Auspex Pharmaceuticals, Inc.NCT02198794Written as SD-809
- Alternatives for Reducing Chorea in Huntington DiseaseCompletedPhase 3Auspex Pharmaceuticals, Inc.NCT01897896Written as SD-809
- A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)CompletedPhase 1Auspex Pharmaceuticals, Inc.NCT02674321Written as SD-809
- Aim to Reduce Movements in Tardive DyskinesiaCompletedPhase 2/3Auspex Pharmaceuticals, Inc.NCT02195700Written as SD-809
- Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and AdolescentsCompletedPhase 2/3Teva Branded Pharmaceutical Products R&D, Inc.NCT03452943Written as TEV-50717
- Symptomatic Therapy for Patients With Huntington's DiseaseStatus unknownPhase 1Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04071639Written as Deutetrabenazine Oral Tablet [Austedo]
- First Time Use of SD-809 in Huntington DiseaseCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01795859Written as SD-809
Codes
What other systems call deutetrabenazine · ClinicalTrials.gg INT000511
- MeSH (NLM) C000609690deutetrabenazineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P341G6W9NBDEUTETRABENAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 1876905One source FDA
- Wikidata Q27077026deutetrabenazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174828DeutetrabenazineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609690 | deutetrabenazine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P341G6W9NB | DEUTETRABENAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1876905 | — | One source FDA |
| Wikidata | Q27077026 | deutetrabenazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174828 | Deutetrabenazine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.